Home LiteratureArticle Details
PMID: 22663012 Published · ppublish English Editorial Comment

Promises from trametinib in RAF active tumors.

The New England journal of medicine ·Vol. 367 ·No. 2 ·2012-07-12 ·Pages 171-2

Sausville EA

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/therapeutic use Female Humans MAP Kinase Kinase 1/antagonists & inhibitors MAP Kinase Kinase 2/antagonists & inhibitors Male Melanoma/drug therapy Protein Kinase Inhibitors/therapeutic use Proto-Oncogene Proteins B-raf/genetics Pyridones/therapeutic use Pyrimidinones/therapeutic use
Chemicals
Antineoplastic Agents Protein Kinase Inhibitors Pyridones Pyrimidinones trametinib MAP2K2 protein, human BRAF protein, human Proto-Oncogene Proteins B-raf MAP Kinase Kinase 1 MAP Kinase Kinase 2 MAP2K1 protein, human
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Sausville Edward A
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJMe1205654
Published
2012-07-12
Epub
2012-00-04
Pages
171-2
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 22663011
External Links
PubMed source DOI: 10.1056/NEJMe1205654 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2